Harvard Bioscience, Inc. - HBIO Net Assets per Single Share

Harvard Bioscience is implementing tissue analysis instruments in collaboration with universities and pharmaceutical laboratories. The total book value per share reflects the net asset trend, where the value of 1.62 characterizes this level. The business relies on stable government grants that mitigate the impact of crises, while growth is driven by the implementation of automation within the biopharmaceutical preclinical research segment.

harvardbioscience.com (HBIO) - Accounting Value per Share from 07/04/2022 to 10/27/2026

Summary analytical data breakdowns for harvardbioscience.com (HBIO)

- price and consensus price forecast:

Stock Price Harvard Bioscience|HBIO - Analyst Median Target

- market capitalization data:

Market Value Harvard Bioscience, Inc.|HBIO - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share Harvard Bioscience|HBIO - Company Net Assets|Market Capitalization to Book Value Ratio harvardbioscience.com|HBIO - Company Assets

- debt and liquidity data:

Total Debt to Capital Harvard Bioscience|HBIO - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Harvard Bioscience, Inc.|HBIO - Company Total Debt Obligations|Debts to Book Capitalization Harvard Bioscience, Inc.

Analysis of all company metrics:Harvard Bioscience - HBIO

Manufactured product of harvardbioscience.com

Assessing the asset quality of Harvard Bioscience (HBIO) requires an analysis of the residual capital value allocated per share after deducting all liabilities. By analyzing the BVPS trend, an investor can discern the real value of net assets, which, combined with portfolio optimization under Jim Green's leadership, allows for an evaluation of equity accumulation efficiency and the business's resilience to market downturns.

Competitors of Harvard Bioscience (HBIO)